ArticleResearch and practice in thrombosis and haemostasis2026
Combined mesenchymal stem cells and telitacicept therapy for Evans syndrome refractory to various immunosuppressive: a case report.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evans syndrome (ES) is a rare autoimmune cytopenia characterized by autoimmune hemolytic anemia and immune thrombocytopenia. Patients who are refractory to multiple immunosuppressive therapies have limited treatment options, and long-term outcomes remain poor. Key Clinical Question: Can combined immunomodulatory therapy with telitacicept and mesenchymal stem cells (MSCs) achieve effective disease control in patients with refractory ES who have failed conventional and advanced therapies? Clinical Approach: A 41-year-old woman with refractory ES, unresponsive to multiple therapies including corticosteroids, intravenous immunoglobulin, rituximab, thrombopoietin receptor agonists, daratumumab, and splenectomy, was treated with combined telitacicept (160 mg weekly) and MSCs (2 × 10 Conclusion: This case suggests that combined therapy with telitacicept and MSCs may represent an effective therapeutic option for patients with refractory ES. The complementary immunosuppressive mechanisms of BAFF/APRIL blockade and MSC-mediated immune regulation may provide synergistic disease control and warrant further investigation in larger clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.